Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick F Finn

Showing results (11-20 of 17) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 17 results.
Molecular Genetics and Metabolism|June 18, 2010
Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe diseaseKaren M Ashe, Kristin M Taylor, Qiuming Chu, et al.
American Journal of Human Genetics|March 19, 2019
Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human PrimatesXuling Zhu, Ling Yin, Matt Theisen, et al.
Journal of Hepatology|December 19, 2020
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4<sup>-/-</sup> mouse model of PFIC3Guangyan Wei, Jingsong Cao, Pinzhu Huang, et al.
American Journal of Human Genetics|August 22, 2023
GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individualsMenno Ter Huurne, Benjamin L Parker, Ning Qing Liu, et al.
Science Translational Medicine|January 10, 2024
mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduriaSonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, et al.
Nature Communications|May 26, 2021
mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage diseaseJingsong Cao, Minjung Choi, Eleonora Guadagnin, et al.
Journal of Inherited Metabolic Disease|December 4, 2023
The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduriaSonam Gurung, Saketh Karamched, Dany Perocheau, et al.
Pageof 2

Showing results (11-20 of 17) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 17 results.
Molecular Genetics and Metabolism|June 18, 2010
Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe diseaseKaren M Ashe, Kristin M Taylor, Qiuming Chu, et al.
American Journal of Human Genetics|March 19, 2019
Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human PrimatesXuling Zhu, Ling Yin, Matt Theisen, et al.
Journal of Hepatology|December 19, 2020
Synthetic human ABCB4 mRNA therapy rescues severe liver disease phenotype in a BALB/c.Abcb4<sup>-/-</sup> mouse model of PFIC3Guangyan Wei, Jingsong Cao, Pinzhu Huang, et al.
American Journal of Human Genetics|August 22, 2023
GLA-modified RNA treatment lowers GB3 levels in iPSC-derived cardiomyocytes from Fabry-affected individualsMenno Ter Huurne, Benjamin L Parker, Ning Qing Liu, et al.
Science Translational Medicine|January 10, 2024
mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduriaSonam Gurung, Oskar Vilhelmsson Timmermand, Dany Perocheau, et al.
Nature Communications|May 26, 2021
mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage diseaseJingsong Cao, Minjung Choi, Eleonora Guadagnin, et al.
Journal of Inherited Metabolic Disease|December 4, 2023
The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduriaSonam Gurung, Saketh Karamched, Dany Perocheau, et al.
Pageof 2